Publications
5898 Results
- Journal / Conference
- Blood Advances 2025 Dec 23;9(24):6443-6454. doi: 10.1182/bloodadvances.2025016827.
- Year
- 2025
- Research Committee(s)
- Lymphoma
- PMID
- 40966421
- PMC
- PMC12755980
- Study Number(s)
- S0016
Development and Validation of a Gene Expression Signature to Predict Early Events in Patients with Follicular Lymphoma
- Journal / Conference
- Prostate Cancer Foundation annual meeting (October 23-25, 2025, Carlsbad, CA)
- Year
- 2025
- Research Committee(s)
- Genitourinary
- Study Number(s)
- CCTG-PR26
Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response
- Journal / Conference
- Journal of Clinical Oncology, 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9.
- Year
- 2025
- Research Committee(s)
- Cancer Survivorship
- PMID
- 40632989
- Study Number(s)
- CTSU/A221405
Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial
- Journal / Conference
- JNCI-Journal of the National Cancer Institute djaf342; publ Dec 4, 2025; 10.1093/jnci/djaf342
- Year
- 2025
- Research Committee(s)
- Cancer Care Delivery
- PMID
- PMID41346251
Development and Validation of a Risk Prediction Model for Acute Care Use Among Older Patients with Advanced Cancer on Clinical Trials
- Journal / Conference
- Nature Cancer. 2026 Feb;7(2):272-282. doi: 10.1038/s43018-025-01113-y. Epub 2026 Jan 29.
- Year
- 2025
- Research Committee(s)
- Melanoma
- PMID
- 41611998
- PMC
- PMC12948668
- Study Number(s)
- S1512
Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A)
- Journal / Conference
- Journal of Clinical Oncology
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1001
Development and validation of a novel conditional event-free survival tool in diffuse large B-cell lymphoma
- Journal / Conference
- Journal for ImmunoTherapy of Cancer. 2025 Dec 21; 13: e013186. DOI: 10.1136/jitc-2025-013186.
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID41423272
- Study Number(s)
- CTSU/C80405
Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data
- Journal / Conference
- Oncologist. 2025 Dec 27; 31: oyaf416. DOI: 10.1093/oncolo/oyaf416.
- Year
- 2025
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID41397917
- Study Number(s)
- CTSU/E3201
Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201
- Journal / Conference
- Annals of Oncology. 2025 Nov 1; 36: 1409-1413. DOI: 10.1016/j.annonc.2025.08.004. Epub 2025 Aug 23
- Year
- 2025
- Research Committee(s)
- Genitourinary
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
- Journal / Conference
- Journal of Clinical Oncology. 2025 Sep 20; 43: 2968-2973. DOI: 10.1200/JCO-25-00204.
- Year
- 2025
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826